Page last updated: 2024-11-05

thiotepa and Neutropenia

thiotepa has been researched along with Neutropenia in 16 studies

Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).

Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.

Research Excerpts

ExcerptRelevanceReference
" The aim of the present study was to evaluate the safety and efficacy of oral fluconazole for empirical antifungal therapy in neutropenic patients with persistent fever."9.11Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation. ( Hardan, I; Maor, Y; Stemmer, SM, 2004)
"We evaluated the pharmacokinetics and pharmacodynamics of high-dose paclitaxel (HDP) monotherapy (825 mg/m2 continuous infusion over 24 h) with peripheral blood progenitor cell (PBPC) and G-CSF support in 17 women with metastatic breast cancer."9.09The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ( Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT, 2001)
"Thirty-eight women with responsive metastatic breast cancer received high-dose cyclophosphamide (3 to 6 g/m2 over 4 days), thiotepa (400 to 800 mg/m2), and novobiocin (0."9.08Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. ( Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995)
"The dose-limiting toxicities were interstitial pneumonitis and mucositis with moderately severe diarrhea (n = 3) and rash (n = 3)."6.69Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. ( Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M, 2000)
" The aim of the present study was to evaluate the safety and efficacy of oral fluconazole for empirical antifungal therapy in neutropenic patients with persistent fever."5.11Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation. ( Hardan, I; Maor, Y; Stemmer, SM, 2004)
"We evaluated the pharmacokinetics and pharmacodynamics of high-dose paclitaxel (HDP) monotherapy (825 mg/m2 continuous infusion over 24 h) with peripheral blood progenitor cell (PBPC) and G-CSF support in 17 women with metastatic breast cancer."5.09The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ( Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT, 2001)
"Thirty-eight women with responsive metastatic breast cancer received high-dose cyclophosphamide (3 to 6 g/m2 over 4 days), thiotepa (400 to 800 mg/m2), and novobiocin (0."5.08Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. ( Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995)
"The study was designed to determine the toxicity, feasibility, and effectiveness of high-dose cyclophosphamide (6 g/m2), thiotepa (500 mg/m2) and carboplatin (800 mg/m2 (CTCb) with hematopoietic rescue as consolidation after standard-dose adjuvant chemotherapy treatment of primary high-risk breast cancer."5.08Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer. ( Escudero, A; Fernández-Rañada, JM; López-Lorenzo, JL; López-Pascual, J; Pérez-Carrión, R; Tomás, JF, 1997)
" We conclude that, independent of effects on neutropenia, severe and cumulative platelet toxicity precludes further escalation of thiotepa dose despite the use of GM-CSF."5.07Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. ( Hudes, GR; LaCreta, FP; McAleer, C; Miller, LL; Nash, S; O'Dwyer, PJ; Ozols, RF; Schilder, R, 1992)
"The dose-limiting toxicities were interstitial pneumonitis and mucositis with moderately severe diarrhea (n = 3) and rash (n = 3)."2.69Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. ( Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M, 2000)
"Chromosomal aberrations were quantitated using traditional Giemsa stain."1.33The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration. ( Balis, F; Bates, S; Cole, D; Egorin, MJ; Flynn, BM; Fojo, T; Knutsen, T; Langham, G; Rao, VK; Ried, T; Steinberg, SM; Wangsa, D, 2005)
"As compared with metastatic breast cancer (MBC), high risk breast cancer showed a 2."1.31Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. ( Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G, 2001)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's9 (56.25)18.2507
2000's6 (37.50)29.6817
2010's1 (6.25)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ferreri, AJ1
Cwynarski, K1
Pulczynski, E1
Ponzoni, M1
Deckert, M1
Politi, LS1
Torri, V1
Fox, CP1
Rosée, PL1
Schorb, E1
Ambrosetti, A1
Roth, A1
Hemmaway, C1
Ferrari, A1
Linton, KM1
Rudà, R1
Binder, M1
Pukrop, T1
Balzarotti, M1
Fabbri, A1
Johnson, P1
Gørløv, JS1
Hess, G1
Panse, J1
Pisani, F1
Tucci, A1
Stilgenbauer, S1
Hertenstein, B1
Keller, U1
Krause, SW1
Levis, A1
Schmoll, HJ1
Cavalli, F1
Finke, J1
Reni, M1
Zucca, E1
Illerhaus, G1
Stemmer, SM1
Maor, Y1
Hardan, I1
Rao, VK1
Knutsen, T1
Ried, T1
Wangsa, D1
Flynn, BM1
Langham, G1
Egorin, MJ2
Cole, D1
Balis, F1
Steinberg, SM1
Bates, S1
Fojo, T1
Ridola, V1
Grill, J1
Doz, F1
Gentet, JC1
Frappaz, D1
Raquin, MA1
Habrand, JL1
Sainte-Rose, C1
Valteau-Couanet, D1
Kalifa, C1
Chang, Q1
Hanks, S1
Akard, L1
Thompson, J1
Harvey, K1
English, D1
Jansen, J1
Kennedy, MJ1
Armstrong, DK1
Huelskamp, AM1
Ohly, K1
Clarke, BV1
Colvin, OM1
Grochow, LB1
Chen, TL1
Davidson, NE1
Spitzer, G1
Dunphy, FR1
Petruska, PJ1
Velasquez, WS1
Adkins, DR1
Williams, SF1
Lee, WJ1
Bender, JG1
Zimmerman, T1
Swinney, P1
Blake, M1
Carreon, J1
Schilling, M1
Smith, S1
Williams, DE1
Oldham, F1
Van Epps, D1
Tomás, JF1
Pérez-Carrión, R1
Escudero, A1
López-Lorenzo, JL1
López-Pascual, J1
Fernández-Rañada, JM1
Stahel, RA1
Jost, LM1
Honegger, H1
Betts, E1
Goebel, ME1
Nagler, A1
Hornedo, J1
Sola, C1
Solano, C1
Lluch, A1
Benavides, M1
López López, J1
García Conde, J1
Cortés-Funes, H1
Vahdat, LT2
Papadopoulos, K1
Balmaceda, C1
McGovern, T1
Dunleavy, J1
Kaufman, E2
Fung, B1
Garrett, T1
Savage, D1
Tiersten, A1
Ayello, J1
Bagiella, E1
Heitjan, D1
Antman, K1
Hesdorffer, C1
Prince, HM1
Rischin, D1
Toner, GC1
Seymour, JF1
Blakey, D1
Gates, P1
Eerhard, S1
Chapple, P1
Quinn, M1
Brettell, M1
Juneja, S1
Wolf, M1
Januszewicz, EH1
Richardson, G1
Scarlett, J1
Briggs, P1
Papadopoulos, KP1
Huang, M1
Troxel, AB1
Balmaceda, CM1
Hesdorffer, CS1
Morabito, F1
Irrera, G1
Oliva, E1
Console, G1
Martino, M1
Pucci, G1
Messina, G1
Barbaro, P1
Palazzo, S1
Iacopino, P1
O'Dwyer, PJ1
LaCreta, FP1
Schilder, R1
Nash, S1
McAleer, C1
Miller, LL1
Hudes, GR1
Ozols, RF1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Tra[NCT01011920]Phase 2126 participants (Actual)Interventional2009-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

12 trials available for thiotepa and Neutropenia

ArticleYear
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:5

    Topics: Acute Kidney Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System

2016
Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation.
    American journal of clinical oncology, 2004, Volume: 27, Issue:4

    Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemo

2004
Maturation of mobilized peripheral blood progenitor cells: preclinical and phase I clinical studies.
    Journal of hematotherapy, 1995, Volume: 4, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Differentiation;

1995
Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:5

    Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos

1995
Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.
    Blood, 1996, Mar-01, Volume: 87, Issue:5

    Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin

1996
Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer.
    Bone marrow transplantation, 1997, Volume: 19, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy,

1997
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm

1997
[Multicentric prospective, randomized study of the role of filgrastim (G-CSF) after transplant of hematopoietic progenitor cells mobilized with G-CSF in patients with cancer of the breast].
    Sangre, 1997, Volume: 42 Suppl 1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modal

1997
Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphami

1998
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
    Bone marrow transplantation, 2000, Volume: 26, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea;

2000
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:1

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under

2001
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:8

    Topics: Aged; Drug Administration Schedule; Drug Evaluation; Female; Granulocyte-Macrophage Colony-Stimulati

1992

Other Studies

4 other studies available for thiotepa and Neutropenia

ArticleYear
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
    Mutation research, 2005, Jun-06, Volume: 583, Issue:2

    Topics: Animals; Area Under Curve; Azure Stains; Bone Marrow Cells; Chromosome Aberrations; Chromosome Paint

2005
High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
    Cancer, 2007, Jul-01, Volume: 110, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Busulfan; Cerebellar Neoplasms; Child

2007
Tandem transplants in solid tumors: marrow versus peripheral stem cell transplant: peripheral blood cells as now practiced are not the whole answer.
    Journal of hematotherapy, 1993,Fall, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Transplantation; Breas

1993
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
    Bone marrow transplantation, 2001, Volume: 28, Issue:9

    Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplast

2001